Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers

Carcinogenesis

Volumn 28, Issue 2, 2007, Pages 289-298

  Dearth, Lawrence R ^a   Qian, Hua ^b   Wang, Ting ^c   Baroni, Timothy E ^d   Zeng, Jue ^a   Chen, Stephanie W ^e   Yi, Sun Young ^a,f   Brachmann, Rainer K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LONDON HEALTH SCIENCES CENTRE   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ALLELE; ARTICLE; CARCINOGENESIS; CELL CULTURE; CONTROLLED STUDY; GENETIC TRANSFECTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MISSENSE MUTATION; MUTANT; PLASMID; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; WILD TYPE;

CELL LINE, TUMOR; GENES, P53; GENES, REPORTER; HUMANS; LOSS OF HETEROZYGOSITY; MUTATION; NEOPLASMS; SACCHAROMYCES CEREVISIAE;

EID: 33847326819     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl132     Document Type: Article

References (60)

1. Prives,C. and Hall,P.A. (1999) The p53 pathway. J. Pathol., 187, 112-126.
2. Vogelstein,B., Lane,D. and Levine,A.J. (2000) Surfing the p53 network. Nature, 408, 307-310.
3. Corcoran,C.A., Huang,Y. and Sheikh,M.S. (2004) The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest. Cancer. Biol. Ther., 3, 721-725.
4. Wei,C.-L., Wu,Q., Vega,V.B. et al. (2006) A global map of p53 transcription-factor binding sites in the human genome. Cell, 124, 207-219.
5. Ho,J. and Benchimol,S. (2003) Transcriptional repression mediated by the p53 tumour suppressor. Cell. Death Differ., 10, 404-408.
6. Erster,S. and Moll,U.M. (2005) Stress-induced p53 runs a transcription-independent death program. Biochem. Biophys. Res. Commun., 331, 843-850.
7. Hamroun,D., Kato,S., Ishioka,C., Claustres,M., Beroud,C. and Soussi,T. (2006) The UMD TP53 database and website: Update and revisions. Hum. Mutat., 27, 14-20.
8. Olivier,M., Eeles,R., Hollstein,M., Khan,M.A., Harris,C.C. and Hainaut,P. (2002) The IARC TP53 database: New online mutation analysis and recommendations to users. Hum. Mutat., 19, 607-614.
9. Cho,Y., Gorina,S., Jeffrey,P.D. and Pavletich,N.P. (1994) Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science, 265, 346-355.
10. Bullock,A.N. and Fersht,A.R. (2001) Rescuing the function of mutant p53. Nat. Rev. Cancer, 1, 68-76.
11. Sigal,A. and Rotter,V. (2000) Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res., 60, 6788-6793.
12. Blagosklonny,M.V. (2000) p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J., 14, 1901-1907.
13. Greenblatt,M.S., Bennett,W.P., Hollstein,M. and Harris,C.C. (1994) Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
14. Hollstein,M., Sidransky,D., Vogelstein,B. and Harris,C.C. (1991) p53 mutations in human cancers. Science, 253, 49-53.
15. Ko,L.J. and Prives,C. (1996) p53: Puzzle and paradigm. Genes Dev., 10, 1054-1072.
16. Campomenosi,P., Monti,P., Aprile,A. et al. (2001) p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene, 20, 3573-3579.
17. Di Como,C.J. and Prives,C: (1998) Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene, 16, 2527-2539.
18. Flaman,J.-M., Robert,V., Lenglet,S., Moreau,V., Iggo,R. and Frebourg,T. (1998) Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. Oncogene, 16, 1369-1372.
19. Friedlander,P., Legros,Y., Soussi,T. and Prives,C. (1996) Regulation of mutant p53 temperature-sensitive DNA binding. J. Biol. Chem., 271, 25468-25478.
20. Ludwig,R.L., Bates,S. and Vousden,K.H. (1996) Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol., 16, 4952-4960.
21. Rowan,S., Ludwig,R.L., Haupt,Y., Bates,S., Lu,X., Oren,M. and Vousden,K.H. (1996) Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J, 15, 827-838.
22. Milner,J. and Medcalf,E.A. (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell, 65, 765-774.
23. Brachmann,R.K., Vidal,M. and Boeke,J.D. (1996) Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc. Natl Acad. Sci. USA, 93, 4091-4095.
24. Aurelio,O.N., Kong,X.T., Gupta,S. and Stanbridge,E.J. (2000) p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines. Mol. Cell. Biol., 20, 770-778.
25. de Vries,A., Flores,E.R., Miranda,B., Hsieh,H.M., van Oostrom,C.T., Sage,J. and Jacks,T. (2002) Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl Acad. Sci. USA, 99, 2948-2953.
26. Lang,G.A., Iwakuma,T., Suh,Y.A. et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell, 119, 861-872.
27. Olive,K.P., Tuveson,D.A., Ruhe,Z.C., Yin,B., Willis,N.A., Bronson,R.T., Crowley,D. and Jacks,T. (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell, 119, 847-860.
28. Scharer,E. and Iggo,R. (1992) Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res., 20, 1539-1545.
29. Ishioka,C., Frebourg,T., Yan,Y.X., Vidal,M., Friend,S.H., Schmidt,S. and Iggo,R. (1993) Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat. Genet., 5, 124-129.
30. Kato,S., Han,S.Y., Liu,W., Otsuka,K., Shibata,H., Kanamaru,R. and Ishioka,C. (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc. Natl Acad. Sci. USA, 100, 8424-8429.
31. Resnick,M.A. and Inga,A. (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc. Natl Acad. Sci. USA, 100, 9934-9939.
32. Robert,V., Mchel,P., Flaman,J.M., Chiron,A., Martin,C., Charbonnier,F., Paillot,B. and Frebourg,T. (2000) High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis. Carcinogenesis, 21, 563-565.
33. Inga,A., Cresta,S., Monti,P., Aprile,A., Scott,G., Abbondandolo,A., Iggo,R. and Fronza,G. (1997) Simple identification of dominant p53 mutants by a yeast functional assay. Carcinogenesis, 18, 2019-2021.
34. Marutani,M., Tonoki,H., Tada,M., Takahashi,M., Kashiwazaki,H., Hida,Y., Hamada,J., Asaka,M. and Moriuchi,T. (1999) Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme. Cancer Res., 59, 4765-4769.
35. Monti,P., Campomenosi,P., Ciribilli,Y., Iannone,R., Inga,A., Abbondandolo,A., Resnick,M.A. and Fronza,G. (2002) Tumour p53 mutations exhibit promoter selective dominance over wild type p53. Oncogene, 21, 1641-1648.
36. Brachmann,R.K., Yu,K., Eby,Y., Pavletich,N.P. and Boeke,J.D. (1998) Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J., 17, 1847-1859.
37. Baroni,T.E., Wang,T., Qian,H., Dearth,L.R., Truong,L.N., Zeng,J., Denes,A.E., Chen,S.W. and Brachmann,R.K. (2004) A global suppressor motif for p53 cancer mutants. Proc. Natl Acad. Sci. USA, 101, 4930-4935.
38. Vidal,M., Brachmann,R.K., Fattaey,A., Harlow,E. and Boeke,J.D. (1996) Reverse two-hybrid and one-hybrid systems to detect dissociation of protein-protein and DNA-protein interactions. Proc. Natl Acad. Sci. USA, 93, 10315-10320.
39. Qian,H., Wang,T., Naumovski,L., Lopez,C.D. and Brachmann,R.K. (2002) Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene, 21, 7901-7911.
40. Kern,S.E., Pietenpol,J.A., Thiagalingam,S., Seymour,A., Kinzler,K.W. and Vogelstein,B. (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science, 256, 827-830.
41. Baker,S.J., Markowitz,S., Fearon,E.R., Willson,J.K. and Vogelstein,B. (1990) Suppression of human colorectal carcinoma cell growth by wildtype p53. Science, 249, 912-915.
42. Dearth,L.R. and DeWille,J. (2003) Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells. J. Biol. Chem., 278, 11246-11255.
43. Bond,G.L., Hu,W., Bond,E.E. et al. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602.
44. Bougeard,G., Baert-Desurmont,S., Tournier,I. et al. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J. Med. Genet., 43, 531-533.
45. Soussi,T., Kato,S., Levy,P.P. and Ishioka,C. (2005) Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat., 25, 6-17.
46. Shiraishi,K., Kato,S., Han,S.Y. et al. (2004) Isolation of temperature-sensitive p53 mutations from a comprehensive missense mutation library. J. Biol. Chem., 279, 348-355.
47. Olivier,M., Goldgar,D.E., Sodha,N., Ohgaki,H., Kleihues,P., Hainaut,P. and Eeles,R.A. (2003) Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Res., 63, 6643-6650.
48. Varley,J.M. (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Hum. Mutat., 21, 313-320.
49. Trkova,M., Foretova,L., Kodet,R., Hedvicakova,P. and Sedlacek,Z. (2003) A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors. Cancer Genet. Cytogenet., 145, 60-64.
50. Varley,J.M., Thorncroft,M., McGown,G., Appleby,J., Kelsey,A.M., Tricker,K.J., Evans,D.G. and Birch,J.M. (1997) A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene. Oncogene, 14, 865-871.
51. Birch,J.M., Blair,V., Kelsey,A.M., Evans,D.G., Harris,M., Tricker,K.J. and Varley,J.M. (1998) Cancer phenotype correlates with constitutional. TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene, 17, 1061-1068.
52. Huang,J., Hu,N., Goldstein,A.M. et al. (2000) High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China. Carcinogenesis, 21, 2019-26.
53. Guan,X.Y., Sham,J.S., Tai,L.S., Fang,Y., Li,H. and Liang,Q. (2003) Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma. Cancer Genet. Cytogenet., 140, 45-48.
54. Konishi,H., Takahashi,T., Kozaki,K., Yatabe,Y., Mitsudomi,T., Fujii,Y., Sugiura,T. and Matsuda,H. (1998) Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers. Oncogene, 17, 2095-2100.
55. Soussi,T. (2003) p53 mutations and resistance to chemotherapy: A stab in the back for p73. Cancer Cell, 3, 303-305.
56. Moll,U.M. and Slade,N. (2004) p63 and p73: Roles in development and tumor formation. Mol. Cancer Res., 2, 371-386.
57. Marin,M.C., Jost,C.A., Brooks,L.A. et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet., 25, 47-54.
58. Bergamaschi,D., Gasco,M., Hiller,L. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402.
59. Russo,A., Bazan,V., Iacopetta,B., Kerr,D., Soussi,T. and Gebbia,N. (2005) The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol., 23, 7518-7528.
60. Olivier,M., Langerod,A., Carrieri,P. et al. (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res., 12, 1157-1167.